Rodrigo Suguimoto Iwami

Rodrigo Suguimoto Iwami

Auto-generated profile, based on publicly available information

Rodrigo Suguimoto Iwami

Nursing Undergraduate Course, University of Sorocaba, Sorocaba, Brazil

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2021 in Travel Medicine and Infectious Disease
Verified
Journal Article
Closed access
MFMaria Raquel Gomes Fernandes
Maria Raquel Gomes Fernandes
LLLuciane Cruz Lopes
Luciane Cruz Lopes
RIRodrigo Suguimoto Iwami
Rodrigo Suguimoto Iwami
MPMariana Del Grossi Paglia
Mariana Del Grossi Paglia
BCBruna Mateus de Castilho
Bruna Mateus de Castilho
CBCristiane de Cássia Bergamaschi
Cristiane de Cássia Bergamaschi

5 March 2022 in Revista Brasileira de Farmácia Hospitalar e Serviços de Saúde
Verified
Journal Article
Open access
PDF file
RIRodrigo S. Iwami
Rodrigo S. Iwami
MMMariana D. Moura
Mariana D. Moura
FSFlavia B. Sorrilha
Flavia B. Sorrilha
CBCristiane C. Bergamaschi
Cristiane C. Bergamaschi
Objective: This systematic review analyzed the effectiveness and the safety of oral corticosteroids in the treatment of rheumatoid arthritis. Method: The search sources were Cochrane (CENTRAL), MEDLINE, EMBASE, CINAHL, Web of Science, among other; in order to identify randomized controlled trials (RCT) that compared the oral use of corticosteroids to placebo or other treatments in adults. Reviewers, in pairs and independently, selected studies, performed data extraction and assessed the risk of bias. Narrative synthesis of data was performed. Results: Thirteen RCT were selected (n=2,393 patients) and more than 50% of them had some risk of bias. Prednisone 5mg and prednisolone 7.5mg seem to improve pain. Physical function improved with the use of prednisone 5mg, 10mg plus methotrexate (MTX) and 30mg plus MTX; and use of prednisolone 5mg, 7.5mg plus disease modifying anti-rheumatic drugs (DMARD). Prednisone 10mg and prednisolone 5mg, 7.5mg, 30mg and 60mg (alone or with DMARD) seems to improve radiological imaging. Prednisone 5mg and prednisolone 7.5mg reduced morning stiffness. Prednisone 5mg and 10mg (plus aurothioglucose), and prednisolone 7.5mg, budesonide 9mg seem to reduce the number swollen joints. Prednisone 5mg and 10mg, prednisolone 5mg and 7.5mg, and budesonide 9mg reduced the number tender joints. Prednisone 10mg and prednisolone 5mg improved grip strength. Prednisone 5mg, prednisolone (plus MTX and ciclosporin) and prednisolone 7.5mg improved quality of life. Prednisolone and budesonide showed larger numbers of common and serious adverse events. Conclusion: Prednisone 5mg and 10mg and prednisolone 5mg and 7.5mg seems to be effective, while prednisone appears to be safer anti-inflammatory to the treatment of rheumatoid arthritis. However, methodological limitations and the combination of different drugs and doses, contributed to limiting the conclusions on these findings.

31 July 2024 in BMJ Open
Verified
Journal Article
Open access
PDF file
JOJardel Corrêa de Oliveira
Jardel Corrêa de Oliveira
MAMaíra Ramos Alves
Maíra Ramos Alves
LLLuis Phillipe Nagem Lopes
Luis Phillipe Nagem Lopes
FMFabiane Motter
Fabiane Motter
RIRodrigo Suguimoto Iwami
Rodrigo Suguimoto Iwami
LLLuciane Cruz Lopes
Luciane Cruz Lopes
Objective There is limited information regarding the incidence of treatment-related adverse events (AE) following antiretroviral therapy (ART) in women. So, this review aimed to describe the incidence of AE of ART in women living with HIV/AIDS. Design Systematic review and meta-analysis. Data sources Medline, Embase, Cochrane Library, Epistemonikos, Lilacs and Who Index, from inception to 9 April 2023. Eligibility criteria We included randomised controlled trials with at least 12 weeks of follow-up and evaluated AE of ART in women at any age living with HIV/AIDS, without restrictions on status, year or language of publication. We excluded post hoc or secondary analyses and open-label extensions without comparator, and trials involving pregnant or breastfeeding women or with a focus on coinfection with tuberculosis, hepatitis B or C. The primary outcomes were the incidence rate of participants with any clinical and/or laboratory AE related or not to ART and treatment discontinuation. Data extraction and synthesis Two independent reviewers extracted data and assessed the risk of bias using Cochrane’s risk of bias tool 2. We used Bayesian random-effects meta-analysis to summarise event rates. Results were presented as event rates per 1000 person-years (95% credibility intervals, 95% CrI). The pooled incidence rate per 1000 person-years adjusted for duration and loss to follow-up was estimated. We assessed the certainty of the evidence using Grading of Recommendations, Assessment, Development and Evaluation. Results A total of 24 339 studies were identified for screening, of which 10 studies (2871 women) met the eligibility criteria, with 11 different antiretrovirals (ARVs) regimens. Seven studies included exclusively women, while in the remaining three, the proportion of women ranged from 11% to 46%. Nine studies received industry funding. The pooled analysis showed a mean incidence rate of ART-related clinical and laboratory AE of 341.60 events per 1000 person-years (95% CrI 133.60–862.70), treatment discontinuation of 20.78 events per 1000 person-years (95% CrI 5.58–57.31) and ART-related discontinuation of 4.31 per 1000 person-years (95% CrI 0.13–54.72). Summary estimates were subject to significant uncertainty due to the limited number of studies and sparse data. The certainty of the evidence was graded as very low for all outcomes assessed. Conclusion Existing randomised trials do not provide sufficient evidence on the incidence rates of safety outcomes from antiretroviral treatment in women living with HIV/AIDS. Large comparative studies in well-characterised populations are needed to provide a more comprehensive landscape of the safety profile of these ARV therapies in women with HIV/AIDS. PROSPERO registration number CRD42021251051.

1 January 2022 in Revista Brasileira de Medicina do Trabalho
Verified
Journal Article
Open access
RIRodrigo Suguimoto Iwami
Rodrigo Suguimoto Iwami
MSMarcus Tolentino Silva
Marcus Tolentino Silva
CBCristiane de Cássia Bergamaschi
Cristiane de Cássia Bergamaschi
Low back pain and work-related musculoskeletal disorders are two of the leading causes of absenteeism worldwide. To determine the prevalence and predictive factors of low back pain and work-related musculoskeletal disorders in Brazilian domestics and cleaners. This population-based cross-sectional study used data from the 2013 and 2019 National Health Survey (Pesquisa Nacional de Saúde), involving a total of 8,160 workers. The prevalence of low back pain and work-related musculoskeletal disorders was calculated based on adjusted prevalence ratio by Poisson regression and 95%CI. The prevalence of lowback pain was 19.1% in 2013 and 20.6% in 2019, while the prevalence of musculoskeletal disorders was 2.2% in 2013 and 2.4% in 2019. Low back pain was associated with older age (prevalence ratio: 1.74; 95%CI 1.44-2.09), poor or very poor self-rated health (prevalence ratio: 2.10; 95%CI 1.76-2.50), holding a prepaid health plan (prevalence ratio: 1.27; 95%CI 1.09-1.47), and moderately severe (prevalence ratio: 2.27; 95%CI 1.84-2.80) or severe (prevalence ratio: 2.32; 95%CI 1.77-3.04) depressive symptoms. Musculoskeletal disorders affected domestics less frequently (prevalence ratio: 0.53; 95%CI 0.40-0.72) and were associated with women (prevalence ratio: 2.50; 95%CI 1.34-4.66), adults (40-59 years) (prevalence ratio: 1.79; 95%CI 1.26-2.55), holding a prepaid health plan (prevalence ratio: 2.31; 95%CI 1.63-3.26), and the presence of moderately severe (prevalence ratio: 4.00; 95%CI 2.34-6.86) or severe (prevalence ratio: 3.63; 95%CI 1.77-7.46) depressive symptoms. Brazilian domestics and cleaners need interventions and improvements in health care given the prevalence of low back pain and musculoskeletal disorders as well as their association with depression.